Those benefits may diminish after discontinuation.2 People with insulin resistance or type 2 diabetes may notice rising glucose levels after stopping GLP-1 treatment
Each treatment is tailored to the individual after a consultation with one of our healthcare professionals
Individual clearance varies based on body composition, kidney function, and liver function, but the Phase 2 trial established the mean half-life at approximately 6 days for the once-weekly subcutaneous dose range of 0.5mg to 12mg
Blood pressure, glycaemic and lipid control A significant decrease in systolic blood pressure was observed throughout the follow-up (7.5 mmHg at six months, p = 0.013
Specialized programs for hormone optimization, mens and womens sexual health, medical weight loss, longevity, and regenerative care all guided by licensed providers and grounded in comprehensive lab work